Non-Muscle Invasive Bladder Cancer Overview

Save information for later
Sign Up

Learn About Non-Muscle Invasive Bladder Cancer

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Non-Muscle Invasive Bladder Cancer Local Doctors?
2900 12th Ave N, Ste 503e, 
Billings, MT 
 77.1 mi
Accepting New Patients

Robert Stockdale is an Urologist in Billings, Montana. Dr. Stockdale and is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urothelial Cancer, and Ureteroscopy. Dr. Stockdale is currently accepting new patients.

Bozeman Health Deaconess Hospital

935 Highland Blvd, 
Bozeman, MT 
 77.7 mi

Gregory Pritham is an Urologist in Bozeman, Montana. Dr. Pritham and is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Ureteroscopy, and Nephrectomy.

 
 
 
 
Learn about our expert tiers
Learn More

Billings Clinic

801 N 29th St, 
Billings, MT 
 77.5 mi
Accepting New Patients

Lawrence Klee is an Urologist in Billings, Montana. Dr. Klee and is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Bladder Reconstruction, and Reconstructive Urology Surgery. Dr. Klee is currently accepting new patients.

What are the latest Non-Muscle Invasive Bladder Cancer Clinical Trials?
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Summary: This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from s...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

Summary: This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P ...